Weight-Loss Drugs May Lower Cancer Risk in Diabetic Patients, Study Finds

The study found that after four years, patients using GLP-1 receptor agonists showed a 7 percent lower risk of developing any of 14 obesity-related cancers.

Boxes for the medications Wegovy and Zepbound in California on May 8, 2025. JoNel Aleccia/AP Photo

A new study suggests that popular weight-loss medications may do more than just help with diabetes and obesity—they could also modestly reduce the risk of developing certain cancers among adults with diabetes, according to findings released Thursday by the American Society of Clinical Oncology (ASCO).

Potential Cancer Prevention

Researchers analyzed health records from more than 170,000 U.S. adults with both obesity and diabetes, focusing on those treated with glucagon-like peptide-1 (GLP-1) receptor agonists—drugs known for managing blood sugar and, more recently, for aiding weight loss. The study compared these patients to a similar group taking dipeptidyl peptidase-4 (DPP-4) inhibitors, a class of diabetes drugs not associated with weight loss.

The study found that after four years, patients using GLP-1 receptor agonists showed a 7 percent lower risk of developing any of 14 obesity-related cancers and an 8 percent lower risk of death from any cause, compared to those taking DPP-4 inhibitors.

The lower cancer risk was more pronounced for colorectal cancers, with 16 percent fewer colon cancer cases and 28 percent fewer rectal cancer cases among the GLP-1 group.

Study Details and Methodology

The research, led by Lucas A. Mavromatis, a medical student at New York University’s Grossman School of Medicine, used data from 43 U.S. health systems collected between 2013 and 2023.

Study participants included adults with a body mass index (BMI) of 30 or higher and a diagnosis of diabetes. Each group—those on GLP-1 receptor agonists and those on DPP-4 inhibitors—consisted of 85,015 patients, matched with similar characteristics to reduce bias.

“This trial raises an intriguing hypothesis: that the increasingly popular GLP-1 medications used to treat diabetes and obesity might offer some benefit in reducing the risk of developing cancer,” said Dr. Robin Zon, president of ASCO. “Though this trial does not establish causation, it hints that these drugs might have a preventative effect. Future research is needed to validate these findings, including in patients who do not have diabetes.”

Obesity, Diabetes, and Cancer Risk

Obesity is a common risk factor for at least 14 types of cancer, including cancers of the esophagus, colon, rectum, stomach, liver, gallbladder, pancreas, kidney, post-menopausal breast, ovary, endometrium, thyroid, as well as multiple myeloma and meningiomas, according to ASCO.

With the prevalence of obesity and diabetes rising, more people are being prescribed GLP-1 receptor agonists. Up to 12 percent of Americans are using such medications, according to the study and the Centers for Disease Control and Prevention.

GLP-1 receptor agonists work by mimicking hormones that regulate appetite and fullness, helping patients lose weight and control blood sugar. However, the medication can cause side effects such as nausea and stomach pain, and it does not work for everyone.

Gender Differences and Next Steps

The study found that the protective effect of GLP-1 receptor agonists was most evident in women, who experienced an 8 percent lower risk of obesity-related cancer and a 20 percent lower risk of death from any cause compared to women on DPP-4 inhibitors.

The difference was not statistically significant in men, however, and researchers said they could not explain the gender disparity.

Lead author Mavromatis highlighted a need for further research on GLP-1 receptor agonists.

“Our results suggest they may modestly cut the chance of developing certain cancers—especially cancers of the colon and rectum—and reduce rates of death due to all causes. These data are reassuring, but more studies are required to prove causation,” he said in the press release.

The research team plans to continue monitoring patients for longer periods and hopes to study the cancer risk for people who take such agonists but do not have diabetes.

The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health and will be presented at the ASCO Annual Meeting in Chicago from May 30 to June 3.

From NTD News